Literature DB >> 14654574

Drug therapy in chronic heart failure.

D B McKenzie1, A J Cowley.   

Abstract

Chronic heart failure is widely recognised as a common and escalating problem that causes major disability and often shortens life. Diuretics and digoxin have formed the mainstay of treatment for many years. Clinical trials have demonstrated that angiotensin converting enzymes and beta-blockers, in selected patients, improve symptoms and reduce mortality. Angiotensin-II antagonists and spironolactone may also have a role in certain individuals. Newer pharmacological approaches to the management of this complex disease are being developed, but await full evaluation.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14654574      PMCID： PMC1742875          DOI： 10.1136/pmj.79.937.634

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  75 in total

1.  Novel neuropeptides in the pathophysiology of heart failure: adrenomedullin and endothelin-1.

Authors:  M C Petrie; S J McClure; M P Love; J J McMurray
Journal:  Eur J Heart Fail       Date:  1999-03       Impact factor: 15.534

2.  Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure.

Authors:  D B Northridge; P F Currie; D E Newby; J J McMurray; M Ford; N A Boon; H J Dargie
Journal:  Eur J Heart Fail       Date:  1999-03       Impact factor: 15.534

3.  The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure.

Authors:  D R McClean; H Ikram; A H Garlick; A M Richards; M G Nicholls; I G Crozier
Journal:  J Am Coll Cardiol       Date:  2000-08       Impact factor: 24.094

4.  Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

Authors:  B Pitt; P A Poole-Wilson; R Segal; F A Martinez; K Dickstein; A J Camm; M A Konstam; G Riegger; G H Klinger; J Neaton; D Sharma; B Thiyagarajan
Journal:  Lancet       Date:  2000-05-06       Impact factor: 79.321

Review 5.  Women and heart failure.

Authors:  L G Richardson; M Rocks
Journal:  Heart Lung       Date:  2001 Mar-Apr       Impact factor: 2.210

6.  Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease.

Authors:  M C Petrie; N Padmanabhan; J E McDonald; C Hillier; J M Connell; J J McMurray
Journal:  J Am Coll Cardiol       Date:  2001-03-15       Impact factor: 24.094

7.  Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure.

Authors:  G Torre-Amione; J B Young; J Durand; B Bozkurt; D L Mann; I Kobrin; C M Pratt
Journal:  Circulation       Date:  2001-02-20       Impact factor: 29.690

8.  Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.

Authors:  J L Rouleau; M A Pfeffer; D J Stewart; D Isaac; F Sestier; E K Kerut; C B Porter; G Proulx; C Qian; A J Block
Journal:  Lancet       Date:  2000-08-19       Impact factor: 79.321

Review 9.  Current role of beta-adrenergic blockers in the management of chronic heart failure.

Authors:  M Packer
Journal:  Am J Med       Date:  2001-05-07       Impact factor: 4.965

10.  Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure.

Authors:  M M Givertz; W S Colucci; T H LeJemtel; S S Gottlieb; J M Hare; M T Slawsky; C V Leier; E Loh; J M Nicklas; B E Lewis
Journal:  Circulation       Date:  2000-06-27       Impact factor: 29.690
View more
  4 in total

1.  Approach to cardiovascular disease prevention in patients with chronic kidney disease.

Authors:  Cristina Karohl; Paolo Raggi
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-08

2.  Enhancing calstabin binding to ryanodine receptors improves cardiac and skeletal muscle function in heart failure.

Authors:  Xander H T Wehrens; Stephan E Lehnart; Steven Reiken; Roel van der Nagel; Raymond Morales; Jie Sun; Zhenzhuang Cheng; Shi-Xiang Deng; Leon J de Windt; Donald W Landry; Andrew R Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-22       Impact factor: 11.205

3.  Protective effect of oxymatrine on chronic rat heart failure.

Authors:  Shu-Ting Hu; Ying Tang; Ya-Feng Shen; Hai-Hang Ao; Jie Bai; Yong-Liang Wang; Yong-Ji Yang
Journal:  J Physiol Sci       Date:  2011-06-22       Impact factor: 2.781

Review 4.  Global mapping of interventions to improve the quality of life of patients with cardiovascular diseases during 1990-2018.

Authors:  Bach Xuan Tran; Son Nghiem; Clifford Afoakwah; Giang Hai Ha; Linh Phuong Doan; Thao Phuong Nguyen; Tuan Thanh Le; Carl A Latkin; Cyrus S H Ho; Roger C M Ho
Journal:  Health Qual Life Outcomes       Date:  2020-07-29       Impact factor: 3.186
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.